Caprolactam Chem

What does Caprolactam Chem do?

Caprolactam Chemicals Ltd is a micro-cap company in the commodity chemicals industry, incorporated in 1988, with net sales of 2 Cr and a market cap of Rs 20 Cr as of March 2025. The company has faced financial challenges, reporting no net profit and a negative return on equity of -13.35%.

Overview:<BR>Caprolactam Chemicals Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in November 1988 and was registered as a sick company by the Board of Industrial and Finance Reconstruction (BIFR) in 2001. As of the latest quarter reported, which is March 2025, the company has net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 13 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.33 <BR>Return on Equity: -13.35% <BR>Price to Book: 3.67<BR><BR>Contact Details:<BR>Address: B/31 MIDC Industrial Area, Taluka - Mahad Raigad Maharashtra : 402302 <BR>Tel: 91-2145-233427 <BR>Email: caprolactumcl@gmail.com <BR>Website: http://www.caprolactam.co.in

Who are in the management team of Caprolactam Chem?

As of March 2022, the management team of Caprolactam Chem includes Z S Bhanushali (Chairperson & Managing Director), S S Bhanushali (Whole Time Director & CFO), V P Adagale, R P Mange, and Poonam Bhavin Bhanushali (all Independent Directors), along with Dolly Dipesh Shah (Company Secretary & Compliance Officer).

As of March 2022, the management team of Caprolactam Chem includes the following individuals:<BR><BR>1. Z S Bhanushali - Chairperson & Managing Director<BR>2. S S Bhanushali - Whole Time Director & Chief Financial Officer<BR>3. V P Adagale - Independent Director<BR>4. R P Mange - Independent Director<BR>5. Poonam Bhavin Bhanushali - Independent Director<BR>6. Dolly Dipesh Shah - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Has Caprolactam Chem declared dividend?

No Dividend History Available

Who are the peers of the Caprolactam Chem?

Caprolactam Chem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries. In terms of returns, India Glycols leads with 150.46% over one year, while Caprolactam Chem has the lowest at -33.11%.

Peers: The peers of Caprolactam Chem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals, India Glycols, Emmessar Biotech, and Link Pharma Chem, while Below Average management risk is noted for Fischer Medical, Caprolactam Chem, Vivid Global, and Kuwer Industries. Growth ratings show that Excellent capital structure is at GHCL, while Average capital structure is found at Tata Chemicals and the rest. Below Average capital structure is noted for Chemplast Sanmar, India Glycols, Fischer Medical, Caprolactam Chem, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.46%, while Caprolactam Chem has the lowest at -33.11%. Caprolactam Chem's return is significantly lower than all peers. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Caprolactam Chem, Emmessar Biotech, and Vivid Global.

What is the technical trend for Caprolactam Chem?

As of June 6, 2025, Caprolactam Chem's technical trend is mildly bearish, supported by bearish MACD and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 6 June 2025, the technical trend for Caprolactam Chem has changed from bearish to mildly bearish. The weekly MACD remains bearish, and the monthly MACD is also bearish, indicating ongoing downward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly chart, but the monthly remains bearish, indicating mixed signals. Dow Theory indicates a mildly bearish stance on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages.

Who are the top shareholders of the Caprolactam Chem?

The top shareholders of Caprolactam Chem include Siddharth Shankarlal Bhanushali with 22.98%, and individual investors who hold 43.84% of the shares. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Caprolactam Chem primarily consist of its promoters, with Siddharth Shankarlal Bhanushali holding the largest share at 22.98%. Additionally, individual investors collectively hold 43.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

How big is Caprolactam Chem?

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr and reported Net Sales of 6.73 Cr with a Net Profit loss of 0.71 Cr in the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 6.73 Cr. However, it experienced a Net Profit loss of 0.71 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

When is the next results date for Caprolactam Chem?

Caprolactam Chem will announce its results on 14 August 2025.

Caprolactam Chem will declare its results on 14 August 2025.

How has been the historical performance of Caprolactam Chem?

Caprolactam Chem has experienced significant declines in net sales and profitability, with net sales dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025, and profit after tax turning negative at -0.71 Cr. The company faces ongoing financial difficulties, reflected in increased liabilities and stagnant cash flow.

Answer:<BR>The historical performance of Caprolactam Chem has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Caprolactam Chem's net sales peaked at 9.84 Cr in March 2023 but have since declined to 6.74 Cr by March 2025. The total operating income followed a similar trend, dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025. The company faced challenges with operating profit, which reached a high of 4.67 Cr in March 2023 but fell to 1.54 Cr by March 2025. Profit before tax also turned negative in March 2025 at -0.68 Cr, contrasting with a profit of 2.97 Cr in March 2023. Consequently, profit after tax reflected a loss of -0.71 Cr in March 2025, down from a profit of 2.55 Cr in March 2023. The company's total liabilities increased from 11.52 Cr in March 2023 to 14.28 Cr in March 2025, while total assets rose slightly from 11.52 Cr to 14.28 Cr in the same period. Cash flow from operating activities remained stagnant, with no cash inflow reported in March 2025, indicating ongoing financial difficulties. Overall, Caprolactam Chem has experienced a decline in sales and profitability, leading to a challenging financial position in recent years.

Is Caprolactam Chem overvalued or undervalued?

As of November 28, 2025, Caprolactam Chem is considered overvalued with a high PE ratio of 2771.50 and other metrics significantly above industry norms, making it a less prudent investment despite a recent 20.14% stock return.

As of 28 November 2025, the valuation grade for Caprolactam Chem has moved from fair to expensive, indicating a shift in perceived value. The company is currently overvalued based on its high PE ratio of 2771.50, a price to book value of 5.21, and an EV to EBITDA of 15.28, which are significantly higher than industry norms. <BR><BR>In comparison, peers such as Sun Pharma have a PE ratio of 38.03 and an EV to EBITDA of 25.17, while Cipla, which is considered attractive, has a PE ratio of 22.71 and an EV to EBITDA of 16.07. The stark contrast in these ratios suggests that Caprolactam Chem is not only overvalued relative to its peers but also lacks the financial performance metrics that would justify such a high valuation. Despite recent strong stock performance, with a one-year return of 20.14% compared to the Sensex's 8.43%, the underlying valuation metrics indicate that the stock is not a prudent investment at its current price.

Are Caprolactam Chemicals Ltd latest results good or bad?

Caprolactam Chemicals Ltd's latest Q4 FY26 results are strong, with a net profit of ₹0.84 crores, a 90.48% increase quarter-on-quarter, and significant revenue growth. However, concerns about high valuation and lack of institutional interest may impact long-term stability.

Caprolactam Chemicals Ltd's latest results for Q4 FY26 indicate a strong performance, showcasing significant improvements across various financial metrics. The company reported a net profit of ₹0.84 crores, which is a remarkable 90.48% increase quarter-on-quarter and a return to profitability compared to the same quarter last year. Revenue also saw substantial growth, increasing by 90.68% year-on-year and 19.92% quarter-on-quarter, reaching ₹3.07 crores.<BR><BR>The operating margin has expanded to 54.07%, the highest in eight quarters, reflecting effective cost management and operational efficiency. Additionally, the profit after tax (PAT) margin improved to 27.36%, a significant recovery from a negative margin in the previous year.<BR><BR>Overall, these results suggest a positive turnaround for Caprolactam Chemicals, indicating that the company is on a recovery path after previous challenges. However, while the operational metrics are encouraging, there are concerns regarding the company's high valuation relative to its earnings and the absence of institutional investor interest, which could affect its long-term stability.

Should I buy, sell or hold Caprolactam Chemicals Ltd?

Why is Caprolactam Chemicals Ltd falling/rising?

As of 02-June, Caprolactam Chemicals Ltd's stock price is rising to Rs 49.42, with a 4.50% increase over the past week. Despite recent gains, concerns about liquidity and declining investor participation persist.

As of 02-June, Caprolactam Chemicals Ltd's stock price is rising, currently at Rs 49.42, reflecting a change of 0.38 (0.77%) upward. The stock has shown a positive performance over the past week, increasing by 4.50%, while the benchmark Sensex has declined by 1.79%. Additionally, in the past month, the stock has risen by 6.12%, contrasting with a 2.94% drop in the Sensex.<BR><BR>Today, the stock opened with a significant gain of 5% and reached an intraday high of Rs 51.49. However, it also experienced volatility, touching a low of Rs 47.49 during the trading session. Despite this fluctuation, the overall trend for the day has been positive, contributing to the current rise in price.<BR><BR>It is important to note that while the stock has performed well recently, it has underperformed its sector by 2.48% today and has shown erratic trading patterns, not trading on 2 out of the last 20 days. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 82.14% against the 5-day average. This suggests that while the stock is currently rising, there are underlying concerns regarding its liquidity and investor interest.

Which are the latest news on Caprolactam Chem?